Investor Presentation January 2026 This presentation contains forward-looking statements within the meaning of the Private Securities litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as "anticipates," believes," "continues," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," " projects," "seeks," "should," "will," "forecas ...

Financial Results - On January 11, 2026, RxSight, Inc. announced preliminary unaudited financial results for Q4 and full-year 2025[6]. - The financial results announcement is not deemed "filed" under the Exchange Act[7]. - The press release is attached as Exhibit 99.1 for further details on the financial results[17]. Executive Appointment - The company appointed Mark Wilterding as Chief Financial Officer effective January 11, 2026, replacing Shelley Thunen[8]. - The press release regarding Mr. Wilterding's appointment was issued on January 11, 2026[15]. Compensation Details - Mr. Wilterding's annual base salary is set at $550,000, with an annual bonus potential of up to 65% of his base salary[10]. - Mr. Wilterding received options to purchase 258,770 shares of common stock and an award of 163,528 restricted stock units[11]. Company Classification - The company is not classified as an emerging growth company under the Securities Act[5]. - The company operates under the Nasdaq Stock Market LLC with the symbol RXST[5]. - The company is expected to file the full text of the Employment Agreement and Severance Agreement in a subsequent periodic report[14].

Core Viewpoint - RxSight, Inc. has announced preliminary unaudited financial and operational results for Q4 and full-year 2025, indicating a positive trajectory in patient treatment and market share despite challenges faced during the year [1][3][8]. Financial Results - Preliminary unaudited revenue for Q4 2025 is expected to be approximately $32.6 million, driven by the sale of 28,611 Light Adjustable Lenses (LAL™/LAL+®), representing a 10% increase in procedure volume compared to Q3 2025 [8]. - Preliminary unaudited revenue for the full year 2025 is expected to be approximately $134.5 million, exceeding previous guidance of $125 to $130 million, with a 12% increase in procedure volume compared to 2024 [8]. - The company installed 1,134 Light Delivery Devices (LDDs) by the end of 2025, with a total of 163 LDDs sold during the year [8]. Market Position and Growth - RxSight holds approximately 10% market share in the premium intraocular lens (IOL) market, with adoption by over 25% of U.S. cataract surgeons [3]. - The company has made significant progress in treating more patients than ever before, positioning itself for sustained long-term growth [3]. Leadership Transition - Mark Wilterding has been appointed as the new Chief Financial Officer, effective January 11, 2026, bringing over 25 years of financial leadership experience [4][5]. - Wilterding's previous role was Senior Vice President of Global Finance for Edwards Lifesciences, where he oversaw various financial operations [5]. Future Outlook - The company is set to announce audited full-year 2025 financial results and guidance for 2026 in February 2026 [7][8].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving RxSight, Inc. and its executives [1] Group 1: Management Changes - RxSight announced the departure of its Chief Financial Officer, Shelley Thunen, who will remain until her successor is appointed or by January 31, 2026 [2] - The departure of Thunen was noted as surprising by financial services firm BTIG, especially given early signs of operational improvement and a recent management reshuffle [2] - The timing of these leadership transitions suggests ongoing commercial challenges for RxSight, potentially delaying a broader recovery into 2026 despite some recent progress [2] Group 2: Stock Performance - Following the announcement of Thunen's departure, RxSight's stock price fell by $1.22 per share, representing a decline of 9.98%, closing at $11.01 per share on December 23, 2025 [3]

Core Insights - RxSight, Inc. announced the transition of Shelley Thunen from her role as Chief Financial Officer, effective until the appointment of her successor or January 31, 2026 [1] - Thunen will continue to support the company as a consultant after her transition [1] Group 1: Company Overview - RxSight, Inc. is focused on providing high-quality customized vision to patients following cataract surgery [3] - The company’s flagship product, the RxSight Light Adjustable Lens system, is the first and only commercially available intraocular lens technology that can be adjusted post-surgery [3] Group 2: Leadership Impact - Thunen has played a crucial role in RxSight's development, helping the company grow from a pre-commercial stage to having over 1,100 Light Delivery Devices (LDDs) in the field and performing over a quarter million procedures [2] - Her leadership was instrumental during significant milestones, including the company's initial public offering in 2021 [2]

Summary of RxSight Conference Call Company Overview - **Company**: RxSight - **Event**: 2025 Piper Sandler Healthcare Conference - **Management Team Present**: Ron Kurtz (President and CEO), Shelley Thunen (CFO), Oliver (Investor Relations) Industry Context - **Industry**: Cataract surgery and premium intraocular lenses (IOLs) - **Market Size**: The premium IOL market is projected to be around $26 billion to $27 billion globally, with significant growth opportunities in international markets [29][32] Key Challenges and Market Dynamics - **Market Contraction**: The general cataract market contracted early in 2025, which is unusual, but has since normalized [4] - **Increased Competition**: Several competitive IOLs were introduced in the premium space, impacting market dynamics. Major players launched new presbyopia-correcting IOLs, leading to enhanced marketing efforts [4][5] - **Adoption Focus**: The company is concentrating on the adoption of its differentiated LAL technology, which currently represents about 10% of the premium IOL space, up from zero a few years ago [6] Financial Guidance and Performance - **Q4 Guidance**: The company anticipates a sequential revenue step down in Q4, which is typically its strongest quarter. Q3 performance exceeded expectations, particularly in LDD sales [7][9] - **2026 Revenue Expectations**: The company has not provided specific guidance for 2026 but expects sequential growth quarter over quarter, with a street estimate of $135 million, representing a 5% year-over-year growth [11][12] Competitive Landscape - **Market Positioning**: The company believes it has a unique position in the premium IOL market, with no direct competition for its LAL technology in the near term [16][17] - **Future Competitors**: While new entrants are expected, they are not anticipated to significantly impact RxSight's market share in the immediate future [14] Sales and Commercial Strategy - **Sales Force Alignment**: The company has aligned its sales and clinical teams to enhance same-store sales growth and utilization of LAL technology [20][21] - **Training and Adoption**: Efforts are focused on training physicians and addressing pushback against adopting LAL technology, emphasizing the clinical outcomes and return on investment [23][25] International Expansion - **International Strategy**: The company has hired a VP of International and is focusing on expanding its presence in Europe and Asia, with recent approvals in the EU and several Asian countries [29][30] - **Market Potential**: The international markets represent a significant growth opportunity, potentially doubling the U.S. market size [32] Financial Metrics - **Gross Margin Insights**: The company reported a high gross margin in Q3, driven by LAL sales, but does not expect this level to be sustainable. Gross margin is influenced by product mix and production volume [38] - **Operational Expenses**: The company is cautious with OpEx but is investing in sales, marketing, and R&D to drive future growth [39] Conclusion - RxSight is navigating a challenging market environment with increased competition and a focus on technology adoption. The company is strategically positioning itself for growth in both domestic and international markets while managing operational efficiencies and financial performance.

Core Insights - RxSight, Inc. is an ophthalmic medical device company focused on providing customized vision solutions for patients post-cataract surgery [3] - The company will participate in the Piper Sandler 37th Annual Healthcare Conference in New York City on December 3, 2025 [1][2] Company Overview - RxSight offers the RxSight Light Adjustable Lens system, which includes the Light Adjustable Lens (LAL/LAL+), Light Delivery Device (LDD™), and accessories, representing the first adjustable intraocular lens technology available commercially [3] - This technology allows for post-surgery adjustments, enabling healthcare providers to tailor vision outcomes for patients [3] Event Participation - Management is scheduled to present at the conference on December 3, 2025, at 12:00 p.m. Eastern Time, with a live and archived webcast available for investors [2]

Core Insights - RxSight, Inc. reported a quarterly loss of $0.04 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.19, marking an earnings surprise of +78.95% [1] - The company generated revenues of $30.34 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 19.02%, although this represents a decline from $35.31 million in the same quarter last year [2] - RxSight shares have declined approximately 73.8% year-to-date, contrasting with a 15.1% gain in the S&P 500 [3] Earnings Outlook - The earnings outlook for RxSight is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.15 on revenues of $28.68 million, and -$0.56 on revenues of $125.7 million for the current fiscal year [7] - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which RxSight belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Data and Key Metrics Changes - RxSight generated third-quarter revenue of $30.3 million, down 14% compared to $35.3 million in the year-ago quarter, and down 10% compared to $33.6 million in the second quarter of 2025 [8] - GAAP net loss in the third quarter of 2025 was $9.8 million, or a loss of $0.24 per share, compared to a GAAP net loss of $6.3 million, or $0.16 per share in the third quarter of 2024 [11] - Gross margin in the third quarter of 2025 was 79.9%, an increase from 71.4% in the year-ago period [9] Business Line Data and Key Metrics Changes - Sold 26,045 Light Adjustable Lenses (LALs), generating $25.7 million in LAL revenue, up 6% compared to the third quarter of 2024 [8] - Sold 25 Light Delivery Devices (LDDs) in the quarter, down 68% from 78 units in the prior year period [8] - LAL revenue represented 85% of total revenue in the third quarter, an increase from 69% in the third quarter of 2024 [8] Market Data and Key Metrics Changes - Approximately 1,100 LDDs are in the field, representing a 25% increase year-over-year [9] - More than 2,000 ophthalmologists implanted the LAL, representing roughly one-fifth of the estimated total number of U.S. cataract surgeons [4] Company Strategy and Development Direction - The company is focusing on strengthening commercial execution in the U.S. while laying groundwork for global growth, particularly in Asia and Europe [4][5] - New practice development and clinical engagement programs have been launched to optimize LAL workflow and enhance clinical confidence [4] - The company aims to strategically expand its base of LDDs and implanting surgeons while positioning customers for sustained growth [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in building a strong foundation for future growth despite challenges, including a decline in Medicare's physician fee for cataract surgery [16] - The company is narrowing its full-year 2025 revenue guidance to $125 million-$130 million, implying a year-over-year decline of 11%-7% [12] - Management anticipates continued interest in premium IOL options, particularly the LAL, as practices adapt to changing reimbursement rates [16] Other Important Information - SG&A expenses in the third quarter of 2025 were $27.3 million, a 7% increase year-over-year, primarily due to rising personnel costs [10] - R&D expenses rose 3% to $9.1 million compared to the third quarter of 2024 [10] Q&A Session Summary Question: What metrics will be used to evaluate the changes being implemented? - The key metric is the number of LAL procedures, along with the number of physicians implanting each quarter [20][21] Question: How will new entrants in the market impact demand for LAL? - Lower reimbursement for traditional cataract surgery is expected to be a tailwind for premium IOLs, with modest long-term impact from new entrants [22][23] Question: What is driving the increase in active surgeons? - The increase is attributed to new LDD sales and existing practices adopting LAL procedures [27][28] Question: What is the outlook for 2026? - While specific guidance for 2026 is not provided, management expects sequential growth in LAL procedures [36] Question: How does the company view the health of the underlying IOL market? - The premium segment is expected to remain strong, while the monofocal segment may be more affected by economic pressures [42] Question: What is the potential for LALs in post-refractive patients? - Post-refractive cases represent 10%-20% of the patient population, indicating a significant opportunity [52][54] Question: How does the company view its penetration in practices? - Some practices have already achieved standard of care with LALs, and the company aims to deepen its presence in existing accounts [57][58]

Sales Performance - The installed base of Light Delivery Devices (LDDs) reached 1,109 as of September 30, 2025, an increase from 888 at the same time in 2024, representing a growth of approximately 25%[107] - For the quarter ended September 30, 2025, the company sold 25 LDDs, a decrease of 53 units compared to the same period in 2024, indicating slower adoption of the RxSight technology[112] - LAL sales increased by 1,491 units year-over-year for the quarter ended September 30, 2025, totaling 26,045 units sold, primarily due to a larger LDD installed base[112] - Total sales for the three months ended September 30, 2025, were $30.34 million, a decrease from $35.31 million in the same period in 2024, reflecting a decline of approximately 14%[118] - Revenue from LALs for the three months ended September 30, 2025, was $25.69 million, compared to $24.23 million in 2024, marking an increase of about 6%[118] - Sales decreased by $5.0 million, or 14.1%, to $30.3 million for the three months ended September 30, 2025, primarily due to a 68% reduction in LDD sales[131] - For the nine months ended September 30, 2025, sales increased by $2.2 million, or 2.2%, to $101.9 million, driven by increased LAL sales[137] Financial Performance - The company expects to incur net losses and negative cash flows from operations in the near future due to increased costs associated with being a public company[110] - Net loss for the three months ended September 30, 2025, was $9.8 million, a 54.9% increase compared to the net loss of $6.3 million for the same period in 2024[131] - For the nine months ended September 30, 2025, net cash used in operating activities was $14.4 million, compared to $12.7 million for the same period in 2024, reflecting a net loss of $29.8 million in 2025 versus $21.5 million in 2024[150][151] - Net cash provided by financing activities for the nine months ended September 30, 2025, was $0.8 million, significantly lower than $120.3 million in 2024, which included proceeds from a public offering of $108.1 million[155][156] Cost and Expenses - SG&A expenses increased by $1.7 million, or 6.8%, to $27.3 million for the three months ended September 30, 2025, mainly due to increased selling and marketing costs[133] - Research and development expenses rose by $0.2 million, or 2.5%, to $9.0 million for the three months ended September 30, 2025, primarily due to increased overhead costs[134] - SG&A expenses for the nine months ended September 30, 2025, increased by $11.7 million, or 16.0%, to $85.0 million, largely due to higher selling and marketing costs[140] - Research and development expenses for the nine months ended September 30, 2025, increased by $4.5 million, or 17.8%, to $29.6 million, mainly due to increased personnel costs[141] Cash and Investments - As of September 30, 2025, the company had cash, cash equivalents, and short-term investments of $227.5 million, with an accumulated deficit of $651.9 million[144] - Net cash provided by investing activities for the nine months ended September 30, 2025, was $26.5 million, primarily from net maturities of short-term investments of $29.2 million, while in 2024, net cash used was $100.6 million due to net purchases of short-term investments of $96.0 million[153][154] - As of September 30, 2025, the company had cash and cash equivalents and short-term investments totaling $227.5 million, with $197.9 million in highly liquid money market and U.S. Treasury securities[165] Operational Strategy - The company plans to continue significant investments in sales, marketing, and research and development to drive adoption and enhance product offerings[110] - Research and development activities are focused on improving the RxSight system and expanding its indications, with potential future acquisitions to complement the product portfolio[109] - The company has integrated its clinical and sales teams into a unified Customer Success Organization to enhance customer experience and support long-term growth[108] - The company is focused on retaining current employees and hiring additional personnel, which may impact future operational capabilities[152] Market Conditions - The company is facing supply chain constraints and inflation, which may impact its ability to manufacture current and new products, potentially affecting financial condition and results of operations[162] - Uncertain macroeconomic conditions, including inflationary pressures and tariffs, may negatively impact the company's financial results and liquidity through 2025 and beyond[163] - The company does not have material exposure to changes in the fair value of cash and cash equivalents and short-term investments due to their short-term nature, with a hypothetical 1.00% change in interest rates not materially affecting interest income[165] - The company has de minimis amounts of revenue and expenses denominated in currencies other than U.S. dollars, indicating limited foreign currency exchange risk[166] - The gross margin is expected to fluctuate based on production volumes and manufacturing costs, with higher margins anticipated as LAL production increases[121] - Gross margin increased to 79.9% for the three months ended September 30, 2025, compared to 71.4% for the same period in 2024, driven by a higher percentage of revenue from LAL sales[132] - Gross margin for the nine months ended September 30, 2025, improved to 76.3% from 70.4% in the same period of 2024, attributed to a favorable product mix[138]